Go Pro
NYSEAMERICAN:STXS

Stereotaxis Q2 2026 Earnings Report

Stereotaxis logo
$1.26 -0.07 (-5.26%)
Closing price 07/31/2026 04:10 PM Eastern
Extended Trading
$1.29 +0.03 (+2.06%)
As of 07/31/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stereotaxis EPS Results

Actual EPS
N/A
Consensus EPS
-$0.03
Beat/Miss
N/A
One Year Ago EPS
N/A

Stereotaxis Revenue Results

Actual Revenue
N/A
Expected Revenue
$8.35 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Stereotaxis Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Tuesday, August 11, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Stereotaxis Earnings Headlines

[URGENT] Mode Mobile terms changing Aug 14
Mode Mobile has secured its Nasdaq ticker, $MODE, while still in the pre-IPO stage. More than 60,000 investors have already put over $100 million into the company, including original Shark Tank investor Kevin Harrington. The company reports 490M+ users, $115M+ in lifetime revenue, and $1B+ earned and saved by users across 170+ countries. Deloitte ranked Mode North America's #1 fastest-growing software company in 2023 after 32,481% growth. Pre-IPO shares are currently priced at 0.52 dollars, but that price is set to change on August 14.tc pixel
STXS Share News Today
See More Stereotaxis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Stereotaxis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Stereotaxis and other key companies, straight to your email.

About Stereotaxis

Stereotaxis (NYSEAMERICAN:STXS), Inc. is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia. In addition to the Niobe platform, Stereotaxis has introduced the Vdrive Robotic™ system and the EPOCH® solution, which further automate catheter control and sheath deflection to streamline workflow in the electrophysiology lab. Stereotaxis also offers training, installation and technical support services to help facilities adopt and optimize use of its robotic navigation technology.

Founded in 1997 and headquartered in St. Louis, Missouri, Stereotaxis has installed systems at leading hospitals and cardiac centers across North America, Europe, the Middle East and Asia-Pacific. The company maintains strategic collaborations with key electrophysiology mapping and imaging partners to advance integration and clinical data collection. Stereotaxis is led by President and Chief Executive Officer Jim Corriveau, whose team brings extensive experience in medical device innovation, regulatory affairs and global product commercialization.

View Stereotaxis Profile